EXACT Therapeutics

EXTX

NO0010852213

Biotechnology & Medical Research

Real-time Oslo Bors Other stock markets 15:45:00 28/06/2024 BST			5-day change	1st Jan Change
7.4 ^NOK	-.--%		-.--%	-38.33%

04-19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

EXACT Therapeutics minutes from Annual General Meeting June 28, 2024

June 28, 2024 at 10:58 am

OSLO, 28 June 2024: EXACT Therapeutics AS ("EXACT-Tx", "the Company" Euronext
Growth: EXTX) held its Annual General Meeting on June 28th 2024 at 10:30 CEST. 

All proposed resolutions were approved.

Please find enclosed the minutes of the meeting including appendices. The
minutes will also be available on the company website: www.exact-tx.com


ENDS
For more information, please contact:

Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

John M. Edminson CFO 
EXACT Therapeutics 
Email: john.edminson@exact-tx.com


About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com

Click here for more information

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	31/10/23	MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	27/09/23	CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	26/09/23	MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation	26/09/23	CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment	06/09/23	MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain	06/09/23	CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study	07/08/23	MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study	07/08/23	CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study	31/07/23	CI
EXACT Therapeutics AS Announces Management Changes	09/06/23	CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022	21/04/23	CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event	28/03/23	CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial	02/02/23	MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial	02/02/23	CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24%	22/12/22	MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy	22/12/22	CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model	22/11/22	CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022	22/09/22	CI
EXACT Therapeutics Appoints Chief Medical Officer	16/09/22	MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022	16/09/22	CI
Norway's Exact Therapeutics Appoints New CFO	31/08/22	MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022	30/08/22	CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project	23/06/22	MT

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Sector

Biotechnology & Medical Research

Calendar

18/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-38.33%	22.28M
MODERNA, INC.	+19.41%	45.51B
IQVIA HOLDINGS INC.	-8.62%	38.52B
LONZA GROUP AG	+38.90%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B